TY - JOUR
T1 - DMTs and Covid-19 severity in MS
T2 - a pooled analysis from Italy and France
AU - the Musc-19
AU - the Covisep study groups
AU - Sormani, Maria Pia
AU - Salvetti, Marco
AU - Labauge, Pierre
AU - Schiavetti, Irene
AU - Zephir, Helene
AU - Carmisciano, Luca
AU - Bensa, Caroline
AU - De Rossi, Nicola
AU - Pelletier, Jean
AU - Cordioli, Cinzia
AU - Vukusic, Sandra
AU - Moiola, Lucia
AU - Kerschen, Philippe
AU - Radaelli, Marta
AU - Théaudin, Marie
AU - Immovilli, Paolo
AU - Casez, Olivier
AU - Capobianco, Marco
AU - Ciron, Jonathan
AU - Trojano, Maria
AU - Stankoff, Bruno
AU - Créange, Alain
AU - Tedeschi, Gioacchino
AU - Clavelou, Pierre
AU - Comi, Giancarlo
AU - Thouvenot, Eric
AU - Battaglia, Mario Alberto
AU - Moreau, Thibault
AU - Patti, Francesco
AU - De Sèze, Jérôme
AU - Louapre, Celine
N1 - Publisher Copyright:
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2021/8
Y1 - 2021/8
N2 - We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
AB - We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
UR - http://www.scopus.com/inward/record.url?scp=85109780004&partnerID=8YFLogxK
U2 - 10.1002/acn3.51408
DO - 10.1002/acn3.51408
M3 - Article
SN - 2328-9503
VL - 8
SP - 1738
EP - 1744
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 8
ER -